Bayh-Dole is more complex than that. The university gets a part of the proceeds if they manage to license the IP. More important: a university (or even a startu

Bayh-Dole is more complex than that. The university gets a part of the proceeds if they manage to license the IP. More important: a university (or even a startup) do not at all have the means to take anything pharmaceutical through clinical testing, once it reaches Stage 2 it's up to Big Pharma, no one else has the means and the financial resources.